Unmet need in the treatment and management of heart failure

Heart failure affects 14.5 million North Americans and 6 million people in Europe. The global market for biomarkers of cardiovascular disease is predicted to reach $7.2 billion by 2018.

The PROOF Centre’s heart failure programs address clinical needs in the following areas:

- Chronic Heart Failure
- Response to HF Therapy
- Acute Heart Failure
- Advanced Heart Failure

We are developing biomarker-based blood tests that are expected to lead to better patient care through appropriate targeted therapies.

www.proofcentre.ca

Blood tests for better management of heart failure

The PROOF Centre is developing prognostic and diagnostic biomarkers for better management of acute and chronic heart failure. Identifying patients early in clinical presentation will allow for more aggressive therapy and slow disease progression. For pharmaceutical companies, our markers can also be used to identify responders to medicines aimed at treating heart failure symptoms.

FIGURE 1. Heart failure programs at a glance.

FIGURE 2. Current cardiac markers (e.g. B-type natriuretic peptide) misclassify a large portion of chronic heart failure patients. Our panel of molecular biomarkers significantly improves the percentage of patients correctly identified as having chronic heart failure.
The PROOF Centre of Excellence is a not-for-profit organization that develops blood tests to better manage patients with heart, lung and kidney disease. With a cross-disciplinary team of people and organizations, including commercial partners, we can speed up the development of these tests, applying them sooner to improve lives.

To learn more, contact
Janet Wilson-McManus, Chief Operating Officer
Janet.Wilson-McManus@hli.ubc.ca
604 806 8328

www.proofcentre.ca